{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: China Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/cn/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/cn/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from China, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:1752052c1be47cf2b17dc5378ca0c54e31ebacb456617c241d7c0031f7da2453", "url": "https://finance.yahoo.com/healthcare/articles/hengrui-pharma-reports-2026-interim-114600503.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hengrui-pharma-reports-2026-interim-114600503.html", "title": "Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum", "content_text": "SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma (\"Hengrui\" or \"the Company\") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the global value of Hengrui's innovation portfolio. Financial Highlights In the first half of 2026, Hengrui reported revenue of RMB15.46 billion. Drug sales revenue was RMB13.95 billion, representing a year-over-year increase of 1.87%. Innovative drug sales increased by 16.38% year-over-year and accounted f", "date_published": "2026-08-19T11:46:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "600276"], "_sharemaestro": {"country": "China", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "600276", "name": "Jiangsu Hengrui Pharmaceuticals Co.,Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/a31b0dd1-0fcb-42c6-adc3-b9e126e87e2f/"}]}}]}